Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases

Next Previous
Trial Profile

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NKX 019 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Myositis; Systemic scleroderma
  • Focus Therapeutic Use
  • Acronyms Ntrust-2
  • Sponsors Nkarta Therapeutics

Most Recent Events

  • 14 May 2025 Protocol was amended to to modify lymphodepletion prior to administration of NKX019 to use of a combination of fludarabine and cyclophosphamide, with the option for eligible patients to continue to receive cyclophosphamide alone as modified lymphodepletion.
  • 26 Mar 2025 According to a Nkarta Therapeutics Media Release, preliminary clinical data from this study is planned for 2H 2025, and is expected to include clinical response with available follow-up from a group of patients of this study.
  • 30 Jan 2025 Planned number of patients changed from 90 to 72.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top